The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $104.06

Today's change+4.42 +4.44%
Updated March 27 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $104.06

Today's change+4.42 +4.44%
Updated March 27 4:00 PM EDT. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc crosses above 50-day moving average

Alnylam Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$4.42 or 4.44% to (U.S.)$104.06 and crossing above its 50-day moving average. Shares have lost 11.41% over the last five days, but have gained 7.28% over the last year to date. This security has outperformed the S&P 500 by 48.31% during the last year.

Key company metrics

  • Open(U.S.) $99.75
  • Previous close(U.S.) $99.64
  • High(U.S.) $104.96
  • Low(U.S.) $99.72
  • Bid / Ask-- / --
  • YTD % change+7.28%
  • Volume850,161
  • Average volume (10-day)825,543
  • Average volume (1-month)675,631
  • Average volume (3-month)742,771
  • 52-week range(U.S.) $47.03 to (U.S.) $121.93
  • Beta1.73
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.14
Updated March 27 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue241178
Total other revenue--------
Total revenue241178
Gross profit--------
Total cost of revenue--------
Total operating expense705652277
Selling / general / administrative1410129
Research & development564641268
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0------
Other operating expenses, total--------
Operating income-46-45-45-269
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-43-44-44-269
Income after tax-21-44-44-251
Income tax, total-2200-18
Net income-21-44-44-251
Total adjustments to net income--------
Net income before extra. items-21-44-44-251
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-21-44-44-251
Inc. avail. to common incl. extra. items-21-44-44-251
Diluted net income-21-44-44-251
Dilution adjustment--000
Diluted weighted average shares77767668
Diluted EPS excluding extraordinary itemsvalue per share-0.28-0.58-0.58-3.70
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.28-0.58-0.58-3.70